This is a working overview of GHRH analogue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-23 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
=== Youth === The top three riders in the final results of each World Tour event's young rider classification received points towards the standings. Six points were awarded to first place, four points to second place and two points to third place.
===== Evidences against the happiness set point theory ===== In recent large panel studies divorce, death of a spouse, unemployment, disability and similar events have been shown to change the long-term subjective well-being, even though some adaptation does occur and inborn factors affect this. Fujita and Diener found that 24% of people changed significantly between the first five years of the study and the last five years. Almost one in four people showed changes in their well-being over the years; indeed sometimes those changes were quite dramatic. Bruce Headey found that 5–6% of people dramatically increased their life satisfaction over a 15- to 20-year period and that the goals people pursued significantly affected their life satisfaction.
Chemical ecology is a vast and interdisciplinary field utilizing biochemistry, biology, ecology, and organic chemistry for explaining observed interactions of living things and their environment through chemical compounds (e.g. ecosystem resilience and biodiversity). Early examples of the field trace back to experiments with the same plant genus in different environments, interaction of plants and butterflies, and the behavioral effect of catnip. Chemical ecologists seek to identify the specific molecules (i.e. semiochemicals) that function as signals mediating community or ecosystem processes and to understand the evolution of these signals. The chemicals behind such roles are typically small, readily-diffusible organic molecules that act over various distances that are dependent on the environment (i.e. terrestrial or aquatic) but can also include larger molecules and small peptides. In practice, chemical ecology relies on chromatographic techniques, such as thin-layer chromatography, high performance liquid chromatography, gas chromatography, mass spectrometry (MS), and absolute configuration utilizing nuclear magnetic resonance (NMR) to isolate and identify bioactive metabolites. To identify molecules with the sought-after activity, chemical ecologists often make use of bioassay-guided fractionation. Today, chemical ecologists also incorporate genetic and genomic techniques to understand the biosynthetic and signal transduction pathways underlying chemically mediated interactions.
Sources: en.wikipedia.org
Recent studies found a clear association between long-term oral (or intravenous) anticoagulant treatment (OAC) and reduced bone quality due to reduction of active osteocalcin. OAC might lead to an increased incidence of fractures, reduced bone mineral density or content, osteopenia, and increased serum levels of undercarboxylated osteocalcin. Furthermore, OAC is often linked to undesired soft-tissue calcification in both children and adults. This process has been shown to be dependent upon the action of K vitamins. Vitamin K deficiency results in undercarboxylation of MGP. Also in humans on OAC treatment, two-fold more arterial calcification was found as compared to patients not receiving vitamin K antagonists. Among consequences of anticoagulant treatment: increased aortic wall stiffness, coronary insufficiency, ischemia, and even heart failure. Arterial calcification might also contribute to systolic hypertension and ventricular hypertrophy. Anticoagulant therapy is usually instituted to avoid life-threatening diseases, and high vitamin K intake interferes with anticoagulant effects. Patients on warfarin (Coumadin) or being treated with other vitamin K antagonists are therefore advised not to consume diets rich in K vitamins.
== History == In 1970, new strains of fungi were isolated from soil samples taken from Norway and from Wisconsin in the US by employees of Sandoz (now Novartis) in Basel, Switzerland. Both strains produced a family of natural products called cyclosporins. Two related components that had antifungal activity were isolated from extracts from these fungi. The Norwegian strain, Tolypocladium inflatum Gams, was later used for the large-scale fermentation of ciclosporin. The immunosuppressive effect of the natural product ciclosporin was discovered on 31 January 1972 in a screening test on immune suppression designed and implemented by Hartmann F. Stähelin at Sandoz. The chemical structure of cyclosporin was determined in 1976, also at Sandoz. The success of the drug candidate ciclosporin in preventing organ rejection was shown in kidney transplants by R.Y. Calne and colleagues at the University of Cambridge, and in liver transplants performed by Thomas Starzl at the Children's Hospital of Pittsburgh. The first patient, on 9 March 1980, was a 28-year-old woman. In the United States, the Food and Drug Administration (FDA) approved ciclosporin for clinical use in 1983. Thomas Starzl's 1992 memoir explains through the eyes of a transplant surgeon that ciclosporin was an epoch-making drug for solid organ allotransplantation. It greatly expanded the clinical applicability of such transplantation by substantially advancing the antirejection pharmacotherapy component.
Acquired C1 esterase inhibitor deficiency Acute urticaria Adrenergic urticaria Anaphylaxis Aquagenic urticaria Autoimmune urticaria Cholinergic urticaria Chronic urticaria (ordinary urticaria) Cold urticaria Dermatographism (dermographism) Episodic angioedema with eosinophilia (Gleich's syndrome) Exercise urticaria (exercise-induced urticaria) Galvanic urticaria Heat urticaria Hereditary angioedema (Quincke's edema) Localized heat contact urticaria Mast cell-independent urticaria Physical urticaria Primary cold contact urticaria Pressure urticaria (delayed pressure urticaria) Reflex cold urticaria Schnitzler syndrome Secondary cold contact urticaria Solar urticaria Systemic capillary leak syndrome Urticarial allergic eruption Urticaria-like follicular mucinosis Vibratory angioedema
Sources: en.wikipedia.org
== Academia == Ettre was a senior lecturer and adjunct professor at several universities; Veszprém University, Budapest, Hungary (1950–1952), the University of Houston, Texas, United States (1986–1968), Johannes Kepler University, Linz Austria, and the Department of Chemical Engineering at Yale University, New Haven, Connecticut, United States (1977–1978, 1988–200?), where he was adjunct professor and research affiliate. Ettre served as an editor of Chromatographia from 1970 – 1994, when he became a member of the journal's advisory board. He served on the editorial advisory boards of the Journal of Chromatographic Science (1963–1994) and the Journal of Liquid Chromatography (1984–1993), and on the editorial advisory boards of LC/GC Magazine in both the North America and Europe editions, as well as of the Magyar Kemikusok Lapja (Hungarian Chemical Journal). He was the author of the column “Milestones in Chromatography,” in LC/GC Magazine from 1999 until 2008. Ettre was a member of the Commission on Analytical Nomenclature of the International Union of Pure and Applied Chemistry (I.U.P.A.C.) from 1982 to 1990, where he was responsible for the development of the "Unified Nomenclature for Chromatography" issued in 1993.
Both faiths give a prominent place to Jesus: Jesus is the central figure of Christianity, and in the Druze faith, Jesus is considered an important prophet of God, being among the seven prophets who appeared in different periods of history.
=== International Cooperation === In February 2011, President Barack Obama and Canadian prime minister Stephen Harper issued a "Declaration on a Shared Vision for Perimeter Security and Economic Competitiveness" and announced the creation of the Canada-United States Regulatory Cooperation Council (RCC) "to increase regulatory transparency and coordination between the two countries." Under the RCC mandate, the FDA and Health Canada undertook a "first of its kind" initiative by selecting "as its first area of alignment common cold indications for certain over-the-counter antihistamine ingredients (GC 2013-01-10)." A more recent example of the FDA's international work is their 2018 cooperation with regulatory and law-enforcement agencies worldwide through Interpol as part of Operation Pangea XI. The FDA targeted 465 websites that illegally sold potentially dangerous, unapproved versions of opioid, oncology, and antiviral prescription drugs to U.S. consumers. The agency focused on transaction laundering schemes in order to uncover the complex online drug network.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.